Wong-BeringerAJacobsRAGuglielmoBJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis1998;27: 603–18.
2.
AndstromEERingdenORembergerMSvahnBMTollemarJ. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses1996;39:185–93.
3.
Package insert. AmBisome (amphotericin B). Deerfield, IL: Fujisawa USA, January 1998.
4.
Package insert. Abelcet (amphotericin B). Princeton, NJ: Liposome, May 1998.
5.
Package insert. Amphotec (amphotericin B). Menlo Park, CA: Sequus Pharmaceuticals, October 1997.
6.
Package insert. DepoCyt (cytarabine). San Diego, CA: DepoTech, April 1999.
7.
Package insert. Doxil (doxorubicin). Menlo Park, CA: Sequus Pharmaceuticals, August 1997.
8.
RansonMRCarmichaelJO'BryneKStewartSSmithDHowellA. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter Phase II trial. J Clin Oncol1997;15:3185–91.
9.
NorthfeltDWDezubeBJThommesJAMillerBJFischlMAFriedman-KienAPegylated—liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized Phase III clinical trial. J Clin Oncol1998;16:2445–51.
10.
UzielyBJeffersSIsacsonRKutschKWei-TsaoDYehoshuaZLiposomal doxorubicin: Antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncol1995;13:1777–85.
11.
Package insert. DaunoXome (daunorubicin). San Dimas, CA: NexStar Pharmaceuticals, April 1996.
12.
FossaSDAassNParoG. A Phase II study of DaunoXome in advanced urothelial transitional cell carcinoma. Eur J Cancer1998;34:1131–2.
13.
EckardtJRCampbellEBurrisHAWeissRRodriguezGIFieldsSMA Phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol1994;17:498–501.
14.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
15.
NexStar Pharmaceuticals. Investigator's brochures: DaunoXome. San Dimas, CA, 1996.
16.
MiyamotoKSchultzEHeathTMitchellMDAlbertineKHStaubNC. Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol1988;64:1143–52.
17.
LevineSJWalshTJMartinezAEichackerPQLopez-BeresteinGNatansonC. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med1991;114:664–6.
18.
CortesJO'BrienSEsteyEGilesFKeatingMKantarjianH. Phase I study of liposomal daunorubicin in patients with acute leukemia. Inv New Drugs1999;17:81–7.
19.
CortesJKantarjianHO'BrienSGilesFKollerCBeranMHigh-dose liposomal daunorubicin and ara-C for refractory or relapsed acute leukemias: A dose searching study (abstract). Blood1998;92(suppl 1):234a.
